drugset / Trial / NCT06208488
A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and device performance of gefurulimab.
Timeline
- Start
- 2023-11-22
- Primary completion
- 2024-09-17
- Completion
- 2024-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefurulimab | Monoclonal antibody | 600 mg | Subcutaneous |
Indications
No indication recorded.